In our study all 30 cases with BRAF V600E mutation showed unequivocal positive cytoplasmic staining in 85–100% tumor cells; all 30 cases with wild-type KRAS and BRAF were negative; 6.7% (4/60) cases with KRAS mutation showed heterogeneous, cytoplasmic/nuclear staining at stain intensity 1. Here, BRAF is linked to neoplasm.